Frontiers in Endocrinology (Jun 2022)

Association Between Plasma Vitamin D2 and Type 2 Diabetes Mellitus

  • Jing-Wan Qi,
  • Bing Huang,
  • Bing Huang,
  • Shuang Wang,
  • Shuang Wang,
  • Dan Song,
  • Dan Song,
  • Jing Xu,
  • Jing Xu,
  • Ying Cui,
  • Ying Cui,
  • Bin Guo

DOI
https://doi.org/10.3389/fendo.2022.897316
Journal volume & issue
Vol. 13

Abstract

Read online

ObjectiveTo investigate the relationship between plasma vitamin D2(VD2) and type 2 diabetes(T2DM).MethodData from electronic medical records of 797 inpatients treated at Sun Yat Sen Memorial Hospital, Sun Yat-sen University between June 24, 2019 and December 24, 2020 were collected, and a total of 596 patients were enrolled after screening based on inclusion and exclusion criteria. Patients were divided into diabetic and non-diabetic groups according to whether they had T2DM. The Wilcoxon rank sum test was finally selected for the analysis of differences between groups according to the distribution of patients’ plasma VD2, and logistic regression models were used to find the corresponding influencing factors.ResultOf the 596 hospitalized patients, 138 (23.15%) were diagnosed with T2DM. The Wilcoxon test showed no statistically significant difference in plasma VD2 concentrations between the T2DM and non-T2DM groups (p=0.833). After adjustment for confounders by multivariate logistic regression, there was still no significant difference in plasma VD2 concentrations between the two groups (P=0.316, OR: 1.15 (0.88,1.49)). The uncorrelated relationship between VD2 and T2DM was not found to change after incorporating 12 indicators, including demographic characteristics, laboratory indicators and complications, into the logistic regression model by 3 steps, even the OR (1.08 (0.92,1.26)) did not change in the 3 models. Similarly, the adjusted ORs agreed that there was no statistical association between VD2 and T2DM.ConclusionVD2 levels are similar in patients with T2DM compared to those without T2DM. Clinical caution should be exercised in giving VD2 supplementation to patients with T2DM unless other diseases requiring VD2 supplementation (e.g., rickets, osteoporosis) are present.

Keywords